Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TA-102 in Plaque Psoriasis
NCT03645499Phase 1Completed
- Start
- Apr 2018
- Primary completion
- Oct 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of TA-102 in plaque psoriasis (5 arms). Primary endpoint: Number of participants with adrenal suppression at 84 days. Started Apr 2018; status: completed.
02
Drugs
TA-102
03
Conditions
plaque psoriasis
Beyond the preview
Go deeper on NCT03645499.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03645499.